We are live on ! Find out more
BDTX icon

Black Diamond Therapeutics
BDTX

74 hedge funds and large institutions have $209M invested in Black Diamond Therapeutics in 2023 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

682% more call options, than puts

Call options by funds: $3.11M | Put options by funds: $398K

415% more capital invested

Capital invested by funds: $40.6M → $209M (+$169M)

300% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 8

54.54% more ownership

Funds ownership: 58.92% → 113.45% (+55%)

48% more funds holding

Funds holding: 50 → 74 (+24)

19% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 16

Holders
74
Holders Change
+24
Holders Change %
+48%
% of All Funds
1.16%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
32
Increased
13
Reduced
16
Closed
8
Calls
$3.11M
Puts
$398K
Net Calls
+$2.71M
Net Calls Change
+$2.67M

Top Buyers

Rank Fund Capital Flow
1
BG
Bellevue Group
Switzerland
+$5.6M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.08M
3
DM
Deerfield Management
New York
+$3.68M
4
RI
RTW Investments
New York
+$3.47M
5
JP Morgan Chase
JP Morgan Chase
New York
+$2.2M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$2.25M
2
Millennium Management
Millennium Management
New York
-$866K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$333K
4
MB
MPM BioImpact
Massachusetts
-$274K
5
NM
Newtyn Management
New York
-$218K
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
1
Bellevue Group
Switzerland
$41.1M +$5.6M +2,740,000 +51%
NMC
2
NEA Management Company
Maryland
$22.5M +$2.04M +1,000,000 +29%
RCM
3
RA Capital Management
Massachusetts
$17.8M +$1.91M +935,850 +36%
AG
4
Artal Group
Luxembourg
$10.3M +$817K +400,000 +24%
BC
5
Boxer Capital
California
$10.2M – – –
Point72 Asset Management
6
Point72 Asset Management
Connecticut
$10.1M +$4.08M +2,000,000 New
DM
7
Deerfield Management
New York
$9.09M +$3.68M +1,800,000 New
RI
8
RTW Investments
New York
$8.59M +$3.47M +1,700,000 New
BlackRock
9
BlackRock
New York
$7.6M +$1.53M +749,052 +99%
Vanguard Group
10
Vanguard Group
Pennsylvania
$7.48M +$1.48M +723,800 +96%
Citadel Advisors
11
Citadel Advisors
Florida
$6.14M +$1.34M +657,637 +118%
JP Morgan Chase
12
JP Morgan Chase
New York
$5.45M +$2.2M +1,079,507 +195,563%
ABG
13
Ally Bridge Group
New York
$4.04M +$1.63M +800,000 New
KCM
14
Kennedy Capital Management
Missouri
$3.79M +$1.53M +751,403 New
CA
15
CHI Advisors
New York
$3.79M +$1.53M +750,000 New
CH
16
CVI Holdings
Delaware
$3.79M +$1.53M +750,000 New
DCM
17
Driehaus Capital Management
Illinois
$3.52M +$1.42M +696,969 New
RSCM
18
Rock Springs Capital Management
Maryland
$2.84M +$1.15M +563,233 New
IC
19
Ikarian Capital
Texas
$2.75M +$1.11M +545,103 New
CS
20
Candriam SCA
Luxembourg
$2.53M +$1.02M +500,009 New
PHP
21
Parkman Healthcare Partners
Connecticut
$2.52M +$1.02M +500,000 New
Verition Fund Management
22
Verition Fund Management
Connecticut
$2.28M +$217K +106,384 +31%
SCM
23
Soleus Capital Management
Connecticut
$2.2M +$888K +435,000 New
EP
24
Eversept Partners
New York
$2.16M +$873K +427,317 New
VA
25
VR Adviser
New York
$1.79M +$722K +353,629 New
1
2 3 4

BDTX Hedge Fund Activity: Q2 2023 in Review

74 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q2 2023, worth a combined $209M — up 415% from $40.6M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new BDTX positions and 8 closed out — a net gain of 24 holders — while 13 added to existing stakes and 16 trimmed.

The largest buyer was Bellevue Group, adding an estimated $5.6M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $2.25M sold.

  • 74 institutional investors held Black Diamond Therapeutics (BDTX) as of Q2 2023, up from 50 in Q1 2023.
  • Funds reported $209M of Black Diamond Therapeutics stock for Q2 2023, up 415% quarter-over-quarter.
  • 32 funds opened new Black Diamond Therapeutics positions in Q2 2023 and 8 closed out, a net change of +24 holders.
  • The largest Black Diamond Therapeutics buyer in Q2 2023 was Bellevue Group, an estimated $5.6M added.
  • The largest Black Diamond Therapeutics seller in Q2 2023 was EcoR1 Capital, an estimated $2.25M sold.

Based on aggregated 13F filings for Q2 2023.